Moreover, MUC1 can be involved in renal tumor development and can be considered as potential markers of ccRCC development and prognostic,25, 26 which provides a foundation for the development of a cancer vaccine (TG4010, based on MUC1 and interleukin‐2) in the first‐line therapy of metastatic ccRCC patients.27 This evidence concerns the gene MUC1 and nonpapillary renal cell carcinoma.